<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02559258</url>
  </required_header>
  <id_info>
    <org_study_id>TUN001-101</org_study_id>
    <nct_id>NCT02559258</nct_id>
  </id_info>
  <brief_title>Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Epsi- Gam in Healthy, Cat-, Dust Mite-, or Bermuda Grass-Allergic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tunitas Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tunitas Therapeutics Australia Pty Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tunitas Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blind, placebo-controlled, single-dose, dose-&#xD;
      escalation study in otherwise healthy cat-, dust mite-, or Bermuda grass-allergic male and&#xD;
      female subjects. There will be five dosing cohorts (0.1, 0.3, 1.0, 3.0 and 10.0 mg/kg), with&#xD;
      eight subjects in each cohort, randomized to either epsi-gam (6 subjects) or placebo (2&#xD;
      subjects) for a total of 40 subjects. The first cohort will receive the starting dose of 0.1&#xD;
      mg/kg epsi-gam or placebo and subsequent cohorts will be recruited sequentially to receive&#xD;
      escalating doses of epsi-gam or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor Decision&#xD;
  </why_stopped>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability will be assessed by monitoring AEs (frequency and severity) and SAEs, vital signs, PFTs</measure>
    <time_frame>From start of study drug administration through Day 57 (+/- 2 days)</time_frame>
    <description>ECGs, clinical laboratory values (including clinically significant changes from baseline) from blood and urine samples, performing physical examinations and pregnancy tests and reviewing concomitant medications.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Allergy and Immunology</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1 mg/kg epsi-gam or placebo (6:2)</intervention_name>
    <description>administered as a single intravenous infusion on Day 1, infused over 30 minutes</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3 mg/kg epsi-gam or placebo (6:2)</intervention_name>
    <description>administered as a single intravenous infusion on Day 1 infused over 30 minutes</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.0 mg/kg epsi-gam or placebo (6:2)</intervention_name>
    <description>administered as a single intravenous infusion on Day 1 infused over 30 minutes</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 mg/kg epsi-gam or placebo (6:2)</intervention_name>
    <description>administered as a single intravenous infusion on Day 1 infused over 60 minutes</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg/kg epsi-gam or placebo (6:2)</intervention_name>
    <description>administered as a single intravenous infusion on Day 1 infused over 120 minutes</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligible subjects must meet all of the following inclusion criteria:&#xD;
&#xD;
          1. Be informed of the nature of the study and provide written informed consent prior to&#xD;
             undergoing screening procedures.&#xD;
&#xD;
          2. Be a healthy male of any race or ethnicity, at least 18 years of age and no more than&#xD;
             65 years of age, inclusively, OR&#xD;
&#xD;
          3. Be a healthy female of any race or ethnicity of non-childbearing potential, at least&#xD;
             18 years of age and no more than 65 years of age, inclusively, OR&#xD;
&#xD;
          4. Be a healthy non-pregnant, non-lactating female of any race or ethnicity of&#xD;
             childbearing potential, at least 18 years of age and no more than 65 years of age,&#xD;
             inclusive, with a negative pregnancy test who agrees to use 2 medically acceptable&#xD;
             forms of birth control from Screening through 57 days after receiving study drug.&#xD;
&#xD;
          5. Have a Body Mass Index (BMI) within the range of 18.5 to 30.0 kg/m2.&#xD;
&#xD;
          6. Have a history of allergic reactivity to cats, dust mite, or Bermuda grass as&#xD;
             expressed by allergic symptoms including rhinitis.&#xD;
&#xD;
          7. Standardized cat allergenic extract (10,000 BAU/mL, ALK- Abello), dust mite allergenic&#xD;
             extract (10,000 AU/mL, ALK- Abello), dust mite allergenic extract (10,000 AU/mL, ALK-&#xD;
             Abello), or Bermuda grass allergenic extract (10,000 BAU/mL, ALK- Abello) elicits a&#xD;
             wheal at least 5 mm up to approximately 10-15 mm in diameter that exceeds two diluent&#xD;
             controls by at least 4 mm.&#xD;
&#xD;
          8. Have allergen-specific IgE for cat, dust mite, or Bermuda grass as measured by&#xD;
             ImmunoCAP® with a Class rating of 1 or greater.&#xD;
&#xD;
          9. Histamine reactivity of 3 mm or greater, with surrounding erythema, on testing using a&#xD;
             standardized epicutaneous delivery device.&#xD;
&#xD;
         10. Be able and willing to discontinue any first and second generation antihistamine use&#xD;
             beginning at least 7 days prior to undergoing initial screening skin puncture tests&#xD;
             and throughout study participation.&#xD;
&#xD;
         11. Have baseline spirometry (FEV1, FVC, FEF 25%-75%) with FEV1 ≥ 80% predicted and other&#xD;
             values within the normal range.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria must be excluded:&#xD;
&#xD;
          1. Diluent control elicits a wheal ≥ 3 mm on testing.&#xD;
&#xD;
          2. History of severe systemic allergic reactions to cats, dust mite, or Bermuda grass&#xD;
&#xD;
          3. Clinical history of persistent asthma&#xD;
&#xD;
          4. Dermatographism or any skin disorder (i.e., atopic dermatitis) that would make skin&#xD;
             testing or proper interpretation impractical.&#xD;
&#xD;
          5. Chronic urticaria.&#xD;
&#xD;
          6. Underlying heart, liver, kidney, or lung disease or any other medical condition such&#xD;
             that the subject would be at increased risk for a poor outcome should a generalized&#xD;
             allergic or other reaction occur.&#xD;
&#xD;
          7. Any abnormal laboratory value(s) considered to be clinically significant by the&#xD;
             Investigator.&#xD;
&#xD;
          8. Use of systemic corticosteroids within the past three months prior to initial&#xD;
             screening.&#xD;
&#xD;
          9. Use of topical corticosteroids on the area(s) to undergo skin tests within the past&#xD;
             three weeks prior to initial screening.&#xD;
&#xD;
         10. Use of systemic beta-blocking or ACE-inhibiting agents within the past three weeks&#xD;
             prior to initial screening.&#xD;
&#xD;
         11. Use of tricyclic antidepressants within the past three weeks prior to initial&#xD;
             screening.&#xD;
&#xD;
         12. Use of H2 antagonists within 24 hours prior to initial screening.&#xD;
&#xD;
         13. Use of any agents known or likely to interact with adrenaline.&#xD;
&#xD;
         14. Use of omalizumab (Xolair®) within the past six months prior to enrolment.&#xD;
&#xD;
         15. Pregnant females as determined by a positive serum or urine hCG test.&#xD;
&#xD;
         16. Lactating females.&#xD;
&#xD;
         17. Participation in another experimental drug or device trial and receipt of an&#xD;
             investigational product within the past 30 days, five half-lives or twice the duration&#xD;
             of the biochemical effect of the investigational product (whichever is longer) prior&#xD;
             to dosing in the present study.&#xD;
&#xD;
         18. Any mental impairment as judged by the Investigator that would limit ability to comply&#xD;
             with study requirements.&#xD;
&#xD;
         19. History of infection with, or positive screen for, Hepatitis B (HBsAg, Hepatitis B&#xD;
             Surface Antigen), Hepatitis C (HCVAb, Hepatitis C Antibody), or Human Immunodeficiency&#xD;
             Virus (HIV 1 or 2).&#xD;
&#xD;
         20. Positive urine screen for drugs of abuse. Positive ethanol breath test.&#xD;
&#xD;
         21. Concurrent disease or condition, that, in the opinion of the Investigator, places the&#xD;
             subject at high risk of poor treatment compliance or of not completing the study.&#xD;
&#xD;
         22. Has smoked or consumed nicotine-containing products within past 3 months prior to&#xD;
             receiving study drug or has a positive urine test for cotinine, and does not agree to&#xD;
             refrain from smoking for the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Q-Pharm</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <last_update_submitted>June 15, 2016</last_update_submitted>
  <last_update_submitted_qc>June 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

